Page 61 - TD-4-2

Tumor Discovery Role of honokiol in combination therapy

generation EGFR inhibitor, osimertinib, with the natural transplant recipients: The past and present. Transpl Int.
product honokiol. Mol Oncol. 2020;14(4):882-895. 2006;19(8):607-620.
doi: 10.1002/1878-0261.12645 doi: 10.1111/J.1432-2277.2006.00330.X
62. Chiang CK, Sheu ML, Lin YW, et al. Honokiol ameliorates 72. Chapman JR, Webster AC, Wong G. Cancer in the transplant
renal fibrosis by inhibiting extracellular matrix and pro- recipient. Cold Spring Harb Perspect Med. 2013;3(7):a015677.
inflammatory factors in vivo and in vitro. Br J Pharmacol.
2011;163(3):586-597. doi: 10.1101/CSHPERSPECT.A015677
73. Penn I, Alexander JW, Blaine K. Post-transplant
doi: 10.1111/J.1476-5381.2011.01242.X
malignancy: The role of immunosuppression. Drug Saf.
63. Wang L, Wang J. Honokiol ameliorates DSS-induced mouse 2000;23(2):101-113.
colitis by inhibiting inflammation and oxidative stress and
improving the intestinal barrier. Oxid Med Cell Longev. doi: 10.2165/00002018-200023020-00002
2022;2022:1755608. 74. Banerjee P, Basu A, Arbiser JL, Pal S. The natural product
doi: 10.1155/2022/1755608 honokiol inhibits calcineurin inhibitor-induced and
Ras-mediated tumor promoting pathways. Cancer Lett.
64. Wang XD, Wang YL, Gao WF. Honokiol possesses potential 2013;338(2):292-299.
anti-inflammatory effects on rheumatoid arthritis and
GM-CSF can be a target for its treatment. Int J Clin Exp doi: 10.1016/J.CANLET.2013.05.036
Pathol. 2015;8(7):7929-7936. 75. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: Of
65. Cheng X, Wang F, Qiao Y, et al. Honokiol inhibits interleukin- feedbacks and cross-talks. Oncogene. 2008;27(41):5527-5541.
induced angiogenesis in the NSCLC microenvironment doi: 10.1038/onc.2008.247
through the NF-κB signaling pathway. Chem Biol Interact.
2023;370:110295. 76. Rozengurt E, Soares HP, Sinnet-Smith J. Suppression of
feedback loops mediated by pi3k/mtor induces multiple
doi: 10.1016/J.CBI.2022.110295 overactivation of compensatory pathways: An unintended
66. Chao LK, Liao PC, Ho CL, et al. Anti-inflammatory consequence leading to drug resistance. Mol Cancer Ther.
bioactivities of honokiol through inhibition of protein 2014;13(11):2477-2488.
kinase C, mitogen-activated protein kinase, and the NF-κB doi: 10.1158/1535-7163.MCT-14-0330
pathway to reduce LPS-induced TNFα and NO expression.
J Agric Food Chem. 2010;58(6):3472-3478. 77. Sabarwal A, Wedel J, Liu K, et al. A Combination therapy
using an mTOR inhibitor and Honokiol effectively
doi: 10.1021/JF904207M induces autophagy through the modulation of AXL and
67. Reyes A, Mohanty A, Pharaon R, Massarelli E. Association Rubicon in renal cancer cells and restricts renal tumor
between immunosuppressive therapy utilized in the growth following organ transplantation. Carcinogenesis.
treatment of autoimmune disease or transplant and cancer 2022;43(4):360-370.
progression. Biomedicines. 2022;11(1):99. doi: 10.1093/CARCIN/BGAB126
doi: 10.3390/BIOMEDICINES11010099 78. Yadav M, Sharma A, Patne K, et al. AXL signaling in cancer:
68. Sprangers B, Nair V, Launay-Vacher V, Riella LV, From molecular insights to targeted therapies. Signal
Jhaveri KD. Risk factors associated with post-kidney Transduct Target Ther. 2025;10(1):37.
transplant malignancies: An article from the cancer-kidney doi: 10.1038/s41392-024-02121-7
international network. Clin Kidney J. 2018;11(3):315-329.
79. Buczek M, Escudier B, Bartnik E, Szczylik C, Czarnecka A.
doi: 10.1093/CKJ/SFX122 Resistance to tyrosine kinase inhibitors in clear cell renal cell
69. Wu C, Shapiro R. Post-transplant malignancy: Reducing carcinoma: From the patient’s bed to molecular mechanisms.
the risk in kidney transplant recipients. Expert Opin Biochim Biophys Acta. 2014;1845(1):31-41.
Pharmacother. 2011;12(11):1719-1729. doi: 10.1016/J.BBCAN.2013.10.001
doi: 10.1517/14656566.2011.569708 80. Oudin MJ, Weaver VM. Physical and chemical gradients in
70. O’Neill JP, Sexton DJ, O’Leary E, et al. Post-transplant the tumor microenvironment regulate tumor cell invasion,
malignancy in solid organ transplant recipients in Ireland, migration, and metastasis. Cold Spring Harb Symp Quant
The Irish Transplant Cancer Group. Clin Transplant. Biol. 2016;81(1):189-205.
2019;33(10):e13669.
doi: 10.1101/SQB.2016.81.030817
doi: 10.1111/CTR.13669
81. Botta GP, Granowicz E, Costantini C. Advances on
71. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, immunotherapy in genitourinary and renal cell carcinoma.
Hanto DW. Post-transplant de novo malignancies in renal Transl Cancer Res. 2017;6(1):17-29.

Volume 4 Issue 2 (2025) 53 doi: 10.36922/td.8152